Overview
In one of the first double-blind, placebo-controlled clinical trials of isolated CBG in humans, a 20mg oral dose of hemp-derived cannabigerol produced statistically significant reductions in subjective anxiety and stress, along with improved verbal memory, without intoxication, cognitive slowing, or motor impairment. The study of 34 healthy adults suggests CBG may influence stress and anxiety pathways without producing typical ‘drug effects.’ Researchers emphasize preliminary nature and need for replication. CBG also shows antimicrobial activity against antibiotic-resistant organisms in lab settings. CBGA’s interaction with PPAR receptors suggests metabolic disorder applications.
Clinical Perspective
💊 CBG: THE CANNABINOID YOU NEED TO KNOW ABOUT
The first-ever double-blind, placebo-controlled human trial of isolated CBG just delivered remarkable results.
💆 Significant reductions in anxiety and stress
🧠 Improved verbal memory performance
🔹 Zero intoxication
🧠 No cognitive slowing
🔹 No motor impairment
💊 Dose: just 20mg of hemp-derived CBG
🔹 34 healthy adults studied
🔹 Also shows antimicrobial activity against resistant bacteria
🔹 CBGA interacts with PPAR receptors — metabolic disorder implications
This is what happens when we fund rigorous cannabinoid research. Minor cannabinoids are not minor medicine.
Have thoughts on this? Share it:
Source: https://realmofcaring.org/cbg-cbga-research-updates-potential-benefits/